Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma

OncoTargets and Therapy

Volumn 7, Issue , 2014, Pages 575-585

  Loong, Herbert H ^a   Yeo, Winnie ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemotherapy; Microtubular stabilization and destabilization; Microtubule binding agents; mTOR inhibition

Indexed keywords

9,10 DIDEHYDROEPOTHILONE D; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRENTUXIMAB VEDOTIN; CABAZITAXEL; CANTUZUMAB MERTANSINE; CAPECITABINE; CISPLATIN; COMBRETASTATIN A4 PHOSPHATE; CREMOPHOR; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; ERIBULIN; ESTRAMUSTINE; IXABEPILONE; LAPATINIB; MICROTUBULE BINDING AGENT; NAVELBINE; OMBRABULIN; PACLITAXEL; SAGOPILONE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERUBULIN; VINBLASTINE; VINCRISTINE; VINDESINE; VINFLUNINE;

ACUTE CORONARY SYNDROME; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATAXIA; BREAST CANCER; CELL DEATH; CELL MOTILITY; CELL SHAPE; CONJUGATE; DRUG DOSE ESCALATION; DRUG ISOLATION; DRUG POTENCY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GENE EXPRESSION PROFILING; HODGKIN DISEASE; HUMAN; INTERPHASE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALIGNANT NEOPLASTIC DISEASE; MICROTUBULE; MITOSIS; MITOSIS SPINDLE; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POLYMERIZATION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN PROCESSING; PROTEIN TARGETING; QT PROLONGATION; REVIEW; TRANSITIONAL CELL CARCINOMA; UNSPECIFIED SIDE EFFECT;

EID: 84898926759     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S46019     Document Type: Review

References (110)

1. He J, Gu D, Wu X, et al. Major causes of death among men and women in China. N Engl J Med. 2005; 353: 1124-1134.
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74-108.
3. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg. 2001; 234: 63-70.
4. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34.
5. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-390.
6. Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012; 48: 1452-1465.
7. Patil MA, Chua MS, Pan KH, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene. 2005; 24: 3737-3747.
8. Tung CY, Jen CH, Hsu MT, Wang HW, Lin CH. A novel regulatory event-based gene set analysis method for exploring global functional changes in heterogeneous genomic data sets. BMC Genomics. 2009; 10: 26.
9. Zhou Q, Ching AK, Leung WK, et al. Novel therapeutic potential in targeting microtubules by nanoparticle albumin-bound paclitaxel in hepatocellular carcinoma. Int J Oncol. 2011; 38: 721-731.
10. Higa GM. The microtubule as a breast cancer target. Breast Cancer. 2011; 18: 103-119.
11. Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin Oncol. 2006; 33: 421-435.
12. Farrell KW, Jordan MA, Miller HP, Wilson L. Phase dynamics at microtubule ends: the coexistence of microtubule length changes and treadmilling. J Cell Biol. 1987; 104: 1035-1046.
13. Margolis RL, Wilson L. Microtubule treadmilling: what goes around comes around. Bioessays. 1998; 20: 830-836.
14. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004; 4: 253-265.
15. Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Updat. 2001; 4: 392-401.
16. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res. 1976; 36: 3798-3802.
17. Bennouna J, Campone M, Delord JP, Pinel MC. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs. 2005; 14: 1259-1267.
18. Ortmann CA, Mazhar D. Second-line systemic therapy for metastatic urothelial carcinoma of the bladder. Future Oncol. 2013; 9: 1637-1651.
19. Bennouna J, Breton JL, Tourani JM, et al. Vinflunine-an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer. 2006; 94: 1383-1388.
20. Blasinska-Morawiec M, Tubiana-Mathieu N, Fougeray R, Pinel MC, Bougnoux P. Phase II study of intravenous vinflunine after failure of first-line vinorelbine based regimen for advanced breast cancer. Breast. 2013; 22: 58-63.
21. Kuznetsov G, Towle MJ, Cheng H, et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 2004; 64: 5760-5766.
22. Cortes J, O'Shaughnessy J, Loesch D, et al; EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators. Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet. 2011; 377: 914-923.
23. Senter PD, Sievers EL. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma. Nat Biotechnol. 2012; 30: 631-637.
24. Erickson HK, Lambert JM. ADME of antibody-maytansinoid conjugates. AAPS J. 2012; 14: 799-805.
25. Erickson HK, Lewis Phillips GD, Leipold DD, et al. The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates. Mol Cancer Ther. 2012; 11: 1133-1142.
26. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012; 30: 2183-2189.
27. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008; 68: 9280-9290.
28. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367: 1783-1791.
29. Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J et al. Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol. 2013: 20; 31(9): 1157-1163.
30. Hoffmann-La Roche. A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). Available from: http://www. clinicaltrials. gov/ct2/show/NCT01120184.
31. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010; 9: 790-803.
32. Rustin GJ, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol. 2003; 21: 2815-2822.
33. Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol. 2003; 21: 4428-4438.
34. Cooney MM, Radivoyevitch T, Dowlati A, et al. Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res. 2004; 10: 96-100.
35. Horwitz SB. Taxol (paclitaxel): mechanisms of action. Ann Oncol. 1994; 5 Suppl 6: S3-S6.
36. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 2001; 37: 1590-1598.
37. Terwogt JM, Nuijen B, Huinink WW, Beijnen JH. Alternative formulations of paclitaxel. Cancer Treat Rev. 1997; 23: 87-95.
38. Gradishar WJ, Krasnojon D, Cheporov S, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol. 2009; 27: 3611-3619.
39. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, Downing KH. The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography. Science. 2004; 305: 866-869.
40. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents. 2002; 2: 123-148.
41. Lee FY, Smykla R, Johnston K, et al. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009; 63: 201-212.
42. Peterson JK, Tucker C, Favours E, et al. In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res. 2005; 11: 6950-6958.
43. Rugo HS, Campone M, Amadori D, et al. A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer. Breast Cancer Res Treat. 2013; 139: 411-419.
44. Mok TS, Choi E, Yau D, et al. Effects of patupilone (epothilone B; EPO906), a novel chemotherapeutic agent, in hepatocellular carcinoma: an in vitro study. Oncology. 2006; 71: 292-296.
45. Zhou Q, Wong CH, Lau CP, et al. Enhanced antitumor activity with combining effect of mTOR inhibition and microtubule stabilization in hepatocellular carcinoma. Int J Hepatol. 2013; 2013: 103830.
46. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures-a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim Biophys Acta. 2000; 1470: M79-M91.
47. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R). J Biol Chem. 1997; 272: 2534-2541.
48. Tsimberidou AM, Lewis N, Reid T, et al. Pharmacokinetics and antitumor activity of patupilone combined with midazolam or omeprazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2011; 68: 1507-1516.
49. Tsimberidou AM, Takimoto CH, Moulder S, et al. Effects of patupilone on the pharmacokinetics and pharmacodynamics of warfarin in patients with advanced malignancies: a phase I clinical trial. Mol Cancer Ther. 2011; 10: 209-217.
50. Chi KN, Beardsley E, Eigl BJ, et al. A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a. Ann Oncol. 2012; 23: 53-58.
51. Melichar B, Casado E, Bridgewater J, et al. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer. 2011; 105: 1646-1653.
52. Forster M, Kaye S, Oza A, et al. A phase Ib and pharmacokinetic trial of patupilone combined with carboplatin in patients with advanced cancer. Clin Cancer Res. 2007; 13: 4178-4184.
53. Ten Bokkel Huinink WW, Sufliarsky J, Smit WM, et al. Safety and efficacy of patupilone in patients with advanced ovarian, primary fallopian, or primary peritoneal cancer: a phase I, open-label, dose-escalation study. J Clin Oncol. 2009; 27: 3097-3103.
54. Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol. 1997; 15: 13-19.
55. Memorial Sloan-Kettering Cancer Center. Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer. NCT00025194. http://www. clinicaltrials. gov/ct2/show/NCT00025194.
56. Clinques universitaires Saint-Luc-Universite Catholique de Louvain. Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer. NCT00541281. http://www. clinicaltrials. gov/ct2/show/NCT00541281.
57. MD Anderson Cancer Center. Combination Chemotherapy With Ketoconazole in Treating Patients With Prostate Cancer. NCT00003084. http://www. clinicaltrials. gov/ct2/show/NCT00003084.
58. Loblaw DA, Walker-Dilks C, Winquist E, Hotte S; Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care: Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review. Clin Oncol (R Coll Radiol). 2013; 25: 406-430.
59. Ruchaud S, Carmena M, Earnshaw WC. Chromosomal passengers: conducting cell division. Nat Rev Mol Cell Biol. 2007; 8: 798-812.
60. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005; 5: 423-435.
61. Kruczynski A, Poli M, Dossi R, et al. Anti-angiogenic, vascular-disrupting and anti-metastatic activities of vinflunine, the latest vinca alkaloid in clinical development. Eur J Cancer. 2006; 42: 2821-2832.
62. Carr BI. Hepatocellular carcinoma: current management and future trends. Gastroenterology. 2004; 127: S218-S224.
63. Song MJ, Chun HJ, Song S, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012; 57: 1244-1250.
64. Prajapati HJ, Dhanasekaran R, El-Rayes BF, et al. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma. J Vasc Interv Radiol. 2013; 24: 307-315.
65. Martin R, Geller D, Espat J, et al. Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology. 2012; 59: 255-260.
66. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol. 2011; 7: 937-945.
67. Poon RT, Borys N. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer. Expert Opin Pharmacother. 2009; 10: 333-343.
68. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child-Pugh A versus B cirrhosis. Gastrointest Cancer Res. 2011; 4: 40-44.
69. Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012; 57: 821-829.
70. Falkson G, Burger W. A phase II trial of vindesine in hepatocellular cancer. Oncology. 1995; 52: 86-87.
71. Saliba F, Paule B, Adam R, et al. Vinflunine in patients with advanced unresectable hepatocellular carcinoma and liver impairment. J Clin Oncol. 2007; 25: 15023.
72. Gagandeep S, Novikoff PM, Ott M, Gupta S. Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines. Cancer Lett. 1999; 136: 109-118.
73. Geng C-X, Zeng Z-C, Wang J-Y. Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cell growth and induces apoptosis. World J Gastroenterol. 2003; 9: 696-700.
74. Belletti B, Nicoloso MS, Schiappacassi M, et al. Stathmin activity influences sarcoma cell shape, motility, and metastatic potential. Mol Biol Cell. 2008; 19: 2003-2013.
75. Chen J, Abi-Daoud M, Wang A, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene. 2013; 32: 1330-1337.
76. Strumberg D, Erhard J, Harstrick A, et al. Phase I study of a weekly 1 h infusion of paclitaxel in patients with unresectable hepatocellular carcinoma. Eur J Cancer. 1998; 34: 1290-1292.
77. Chao Y, Chan WK, Birkhofer MJ, et al. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer. 1998; 78: 34-39.
78. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ, Milas L. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst. 1996; 88: 1308-1314.
79. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996; 2: 1843-1849.
80. Luitpold Pharmaceuticals. Taxoprexin® Treatment for Advanced Primary Cancers of the Liver. Availiable from http://www. clinicaltrials. gov/ct2/show/NCT00422877 as accessed on 25 Feb 2014.
81. Cheng KL, Bradley T, Budman DR. Novel microtubule-targeting agents-the epothilones. Biologics. 2008; 2: 789-811.
82. Venook AP, Poon R, Kang YK, et al. Evaluation of patupilpone as monotherapy in patients with advanced hepatoceullar carcinoma (HCC). J Clin Oncol. 2007; 25: 15055.
83. Aihara A, Tanaka S, Yasen M, et al. The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma. J Hepatol. 2010; 52: 63-71.
84. Tanaka S, Arii S, Yasen M, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008; 95: 611-619.
85. Tanaka S, Noguchi N, Ochiai T, et al. Outcomes and recurrence of initially resectable hepatocellular carcinoma meeting milan criteria: rationale for partial hepatectomy as first strategy. J Am Coll Surg. 2007; 204: 1-6.
86. Girdler F, Gascoigne KE, Eyers PA, et al. Validating Aurora B as an anti-cancer drug target. J Cell Sci. 2006; 119: 3664-3675.
87. Mita M, Gordon M, Rejeb N, et al. A phase l study of three different dosing schedules of the oral aurora kinase inhibitor MSC1992371A in patients with solid tumors. Target Oncol. Epub July 6, 2013.
88. Foran J, Ravandi F, Wierda W, et al. A Phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of Aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk. Epub November 14, 2013.
89. Friedberg JW, Mahadevan D, Cebula E, et al. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B-and T-cell non-Hodgkin lymphomas. J Clin Oncol. 2014; 32: 44-50.
90. VanderWeele DJ, Zhou R, Rudin CM. Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin. Mol Cancer Ther. 2004; 3: 1605-1613.
91. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer. 2004; 4: 335-348.
92. Sahin F, Kannangai R, Adegbola O, Wang J, Su G, Torbenson M. mTOR and P70 S6 kinase expression in primary liver neoplasms. Clin Cancer Res. 2004; 10: 8421-8425.
93. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2010; 27: 255-261.
94. Buitrago-Molina LE, Vogel A. mTor as a potential target for the prevention and treatment of hepatocellular carcinoma. Curr Cancer Drug Targets. 2012; 12: 1045-1061.
95. Faivre S, Kroemer G, Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006; 5: 671-688.
96. Buitrago-Molina LE, Pothiraju D, Lamle J, et al. Rapamycin delays tumor development in murine livers by inhibiting proliferation of hepatocytes with DNA damage. Hepatology. 2009; 50: 500-509.
97. Kirstein MM, Boukouris AE, Pothiraju D, et al. Activity of the mTOR inhibitor RAD001, the dual mTOR and PI3-kinase inhibitor BEZ235 and the PI3-kinase inhibitor BKM120 in hepatocellular carcinoma. Liver Int. 2013; 33: 780-793.
98. Zhu AX, Abrams TA, Miksad R, et al. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer. 2011; 117: 5094-5102.
99. Novartis. Global Study Looking at the Combination of RAD001 Plus Best Supportive Care (BSC) and Placebo Plus BSC to Treat Patients With Advanced Hepatocellular Carcinoma. (EVOLVE-1). http://www. clinicaltrials. gov/ct2/show/NCT01035229-As accessed on 25 Feb 2014.
100. Zhu AX, Kudo M, Assenat E, et al. EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib. J Clin Oncol. 2014; 32(Suppl 3). In: ASCO Gastrointestinal Cancers Symposium 2014: January 16-18, 2014; San Francisco, CA. Abstract 172.
101. Yeo W, Chan SC, Mo F, et al. A phase I/II study of mTOR inhibitor temsirolimus in patients with unresectable hepatocellular carcinoma (HCC). ESMO 15th World Congress on Gastrointestinal Cancer; Barcelona. 3-6 July 2013; iv32.
102. Kelley RK, Nimeiri HS, Munster PN, et al. Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates. Ann Oncol. 2013; 24: 1900-1907.
103. University of California, San Francisco. Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma. http://http://www. clinicaltrials. gov/ct2/show/NCT01687673-As accessed on Feb 25, 2014.
104. Mabuchi S, Altomare DA, Connolly DC, et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res. 2007; 67: 2408-2413.
105. Tam KH, Yang ZF, Lau CK, Lam CT, Pang RW, Poon RT. Inhibition of mTOR enhances chemosensitivity in hepatocellular carcinoma. Cancer Lett. 2009; 273: 201-209.
106. Zhou Q, Lui VW, Lau CP, et al. Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma. Biochem Pharmacol. 2012; 83: 1146-1158.
107. Canta A, Chiorazzi A, Cavaletti G. Tubulin: a target for antineoplastic drugs into the cancer cells but also in the peripheral nervous system. Curr Med Chem. 2009; 16: 1315-1324.
108. Argyriou AA, Koltzenburg M, Polychronopoulos P, Papapetropoulos S, Kalofonos HP. Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit Rev Oncol Hematol. 2008; 66: 218-228.
109. Larkin JM, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol. 2007; 18 Suppl 5: v28-v34.
110. Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin Investig Drugs. 2006; 15: 691-702.